Skip to main content

Table 1 (abstract O2) Efficacy in KEYNOTE-045

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

End point

Pembrolizumab

N = 270

Chemotherapy

N = 272

OS, no. of events

155

179

 Median (95 % CI), months

10.3 (8.0-11.8)

7.4 (6.1-8.3)

 HR (95 % CI)

0.73 (0.59-0.91); P = 0.0022

PFS, no. of events

218

219

 Median (95 % CI), months

2.1 (2.0-2.2)

3.3 (2.3-3.5)

 HR (95 % CI)

0.98 (0.81-1.19); P = 0.42

ORR (95 % CI)

21.1 % (16.4-26.5)

11.4 % (7.9-15.8)

 Treatment difference, % (95 % CI)

9.6 (3.5-15.9); P = 0.0011

Back to article page